Like : 0

New staging system can inform treatment decisions for non-metastatic prostate cancer

Doctors and biostatisticians at the University of Michigan Rogel Cancer Center have led the development and validation of a staging system to better predict outcomes and inform treatment decisions for men diagnosed with non-metastatic prostate cancer.

Although it is one of the most common cancers worldwide, prostate cancer remains one of the few major cancers for which the familiar, numerical staging system -; ranging from stage 1 to stage 4 -; has not been adopted into national guidelines for treatment or for the testing of new medicines in clinical trials.

Date and Time : 8/23/2019 5:06:21 PM

Reference : Tazea

Submit your comments